Lipoidic Cells Ovary Cancer, Clinic Case and Literature Review

• Arturo Novoa Vargas

  Oncology Surgeon, Oncology Service in General Regional, HGR No. 196, Social Security Mexican Institute, IMSS, Ecatepec, Edo. Méx., México

• Karla Sánchez Bautista

  Anatomical-Patology Service, HGR No. 196, IMSS., Ecatepec, Edo. Méx., México

• Ismael Coudillo Luna

  Anatomical-Patology Service, HGR No. 196, IMSS., Ecatepec, Edo. Méx., México

 Objective:Analyzed a case of woman with virilizan ovary tumor, where clinics manifestations made easy diagnosis of a anexial tumor producing masculine hormones with neoplastic thorax effusion and ascites. Specific tumoral serum marks for diagnosis, and posoperatory evolution. We made a medical prospective literature review.

Methods:We studied a female case 35 years old, with an androgenic malignity ovary tumor, Analysis was worked ina Regional General Hospital of a State of Mexico, Mexico last year. Prospective studying a tumor of the ovary, produces masculine hormones.

Discussion:Rare tumor, represents, almost 0.5% all ovarian tumors. Its secrets masculine hormones; with broaden voice, acne, facial and corporal hair increased, large clitoris, androgenic calvicie patter. Those tumors grow in all ages women groups, but usually in young women, almost is unilateral (95%). We show a clinical case of woman, 35 years old with androgenic dates, She carried out surgery for ovarian tumor. Histopathology report confirmed a malign ovary cordons sexual cells, with high malign grade compound, approximated 30 cm mayor diameter with integral capsule. Stage IC. Were used 6 cycles intravenous systemic chemotherapy. At present, her tumoral marks are negative and gradually have been disappeared androgenic clinical manifestations.

Conclusions:Rare malign ovary tumor, produces androgenic clinical manifestation. Grove up tumor marks like serum testosterone; cytorreductive surgery is cornerstone treatment. Prognosis disease is up to grade of cell differentiation and stage in surgical-pathological events. Five years survive in stage I, is approximate in 70 to 90% of cases.

Bulun SE, Adashi EY. The physiology and pathology of the female reproductive axis. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, Eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, Pa: Saunders Elsevier 2008; chap 16.

Coleman RL, Gershenson DM. Neoplastic diseases of the ovary: screening, benign and malignant epithelial and germ cell neoplasms, sex-cord stromal tumors. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM, Eds. Comprehensive Gynecology. 5th ed. Philadelphia, Pa: Mosby Elsevier 2007; chap 33. http://dx.doi.org/10.1016/B978-0-323-02951-3.50036-4

Thrall MM, De Loia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian carcinoma. Gynecol Oncol 2007; 105: 17-22. http://dx.doi.org/10.1016/j.ygyno.2006.10.060

Registro Histopatológico de Neoplasias en México 2000. Dirección General de Epidemiología. Secretaría de Salud. www.dgepi.salud.gob.mx/divent/DIVEENT-INDEX.htm

Arrenoblastoma (tumor de Sertoli-Leydig, células lipoídicas) reporte de un caso y revisión de la literatura. Jorge E. Fuentes Aguilar, Adriana Santos Lartigue, Mayra E. Pérez Rosas, Amparo Lomas Flores, Antonio César Escobar Moreno. Patología Revista latinoamericana Volumen 47, núm. 2, abril-junio, 2009.

Rosai J. Female reproductive system. In Ackerman’s Surgical Pathology. Eight edition. Vol. 2. Chap. 19:1513-8. Mosby-Year book. St. Louis. Young RH; Scully RE. Sex cord-stromal, Steroid cell, and other ovaries tumors with endocrine, paraendocrine and paraneoplastic manifestations. In Blaustein’s pathology of the female genital tract. Fourth edition. RJ. Kurmann. Spingler Verlag. New York. 803-14.

Young RH, Clement PB, Scully RE. The ovary. In Diagnostic Surgical Pathology. Sternberg, Philadelphia. Third edition. Vol. Chap. 54: 2351-4.

• PDF